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Abstract
Introduction: Recent studies revealed that co-morbidity and mortality due to cardiovascular disease are increased
in patients with rheumatoid arthritis (RA) but little is known about factors involved in these manifestations. This
study aimed at characterizing the impact of arthritis on oxidative stress status and tissue fibrosis in the heart of rats
with adjuvant-induced arthritis (AIA).
Methods: AIA was induced with complete Freund’s adjuvant in female Lewis rats. Animals were treated by oral
administration of vehicle or angiotensin-converting enzyme inhibitor ramipril (10 mg/kg/day) for 28 days,
beginning 1 day after arthritis induction. Isolated adult cardiomyocytes were exposed to 10 μM 4-hydroxynonenal
(HNE) for 24 hours in the presence or absence of 10 μM ramipril.
Results: Compared to controls, AIA rats showed significant 55 and 30% increase of 4-HNE/protein adducts in
serum and left ventricular (LV) tissues, respectively. Cardiac mitochondrial NADP+-isocitrate dehydrogenase
(mNADP-ICDH) activity decreased by 25% in AIA rats without any changes in its protein and mRNA expression. The
loss of mNADP-ICDH activity was correlated with enhanced accumulation of HNE/mNADP-ICDH adducts as well as
with decrease of glutathione and NADPH. Angiotensin II type 1 receptor (AT1R) expression and tissue fibrosis were
induced in LV tissues from AIA rats. In isolated cardiomyocytes, HNE significantly decreased mNADP-ICDH activity
and enhanced type I collagen and connective tissue growth factor expression. The oral administration of ramipril
significantly reduced HNE and AT1R levels and restored mNADP-ICDH activity and redox status in LV tissues of AIA
rats. The protective effects of this drug were also evident from the decrease in arthritis scoring and inflammatory
markers.
Conclusion: Collectively, our findings disclosed that AIA induced oxidative stress and fibrosis in the heart. The fact
that ramipril attenuates inflammation, oxidative stress and tissue fibrosis may provide a novel strategy to prevent
heart diseases in RA.
Introduction
Rheumatoid arthritis (RA) is a common, systemic, autoim-
mune disease that leads to joint inflammation and pro-
gressive cartilage and bone erosion [1]. RA can also cause
tissue inflammation around the joints as well as in other
organs of the body [2]. Premature mortality among RA
patients is frequently due to cardiovascular (CV) diseases
and congestive heart failure (HF) [3,4]. In particular, given
recent appreciation of the important role of inflammatory
processes in the development and progression of athero-
sclerosis, interest has been focused on CV risk that might
be associated with systemic inflammation in RA patients
[5]. Abnormalities in the left ventricular (LV) structure
and functions have also been reported in this population
[6]. LV hypertrophy predicts CV events independently of
traditional risk factors and therefore, if present, may also
contribute to the early CV morbidity and mortality seen in
RA patients [7]. This may provide a rationale for therapeu-
tic interventions at an early stage of the disease process
before overt CV disease has developed. In this regard,
angiotensin-converting enzyme (ACE) inhibitors have
been reported to improved endothelial function in patients
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with RA [8]. In addition to their effects on blood pressure,
cardiac function, and antiproteinuric effect, ACE inhibitors
have anti-inflammatory and immunomodulating proper-
ties [9]. However, much remains to be learned on the
beneficial role of ACE inhibitors in preventing CV compli-
cations in RA patients.
Over the past 30 years, extensive experimental evi-
dence has accumulated supporting the involvement of
oxidative stress in the pathogenesis of RA and CV dis-
eases [10-14]. Markers of oxidative stress contribute to
and are correlated with disease activity in RA patients
[15]. Oxidative stress contributes to chronic inflamma-
tion of tissues, plays a central role in dyslipidemia and
atherosclerosis [16,17] and causes immunomodulation,
which may lead to autoimmune diseases such as RA
[18,19]. Furthermore, it contributes in T-cell activation
that subsequently leads to endothelial dysfunction,
decrease in endothelial progenitor cells and arterial stiff-
ness, which are the congeners of accelerated athero-
sclerosis observed in RA patients.
One oxidative stress-related molecule that has gener-
ated considerable research interest over the past 10
years is 4-hydroxynonenal (HNE) [20]. HNE is an alde-
hyde end-product generated by peroxidation of the most
abundant class of n-6 polyunsaturated fatty acids [21].
Similar to free radicals, aldehydes are electrophiles that
react readily to nucleophilic residues of proteins, nucleic
acids, and lipids, but their relatively longer half-life
makes them candidates for the propagation of the
damage to neighboring cells. The interest for HNE
stems not only from its potential use as a biomarker of
oxidative stress-induced lipid peroxidation (LPO), but
also because of accumulating evidence indicating that
HNE is able to modulate signaling pathways involved in
cell proliferation, apoptosis, and inflammation, which
are hallmarks of CV diseases [22,23]. However, much
remains to be learned on the role of HNE as an active
biomarker of oxidative stress-related events in RA
patient that have an increased risk of developing CV
diseases.
The principal aim of this study is to make a bridge
between RA and cardiac complications by studying the
involvement of HNE. Although accumulating evidence
indicates that LPO products including HNE are increased
and closely associated with RA, little data are available on
the accumulation and the impact of this aldehyde in car-
diac tissues in humans or animals with RA. Therefore, the
present study aims to investigate the production of HNE
in LV tissues from adjuvant-induced arthritis (AIA) rats
and to identify a cellular target of HNE, namely the car-
diac mitochondrial NADP+-dependent isocitrate dehydro-
genase (mNADP-ICDH). We propose that accumulation
of HNE in the heart may affect antioxidant status and cell
metabolism and induce tissue fibrosis. In addition, we
evaluated whether ramipril, an ACE inhibitor, reverses RA
scores and prevents elevation of markers of oxidative
stress, inflammation and tissue fibrosis.
Materials and methods
Adjuvant-induced arthritis (AIA) in rats
A total of 30 female Lewis rats (Charles River, Montreal,
QC, Canada), weighing between 220 to 240 g, were stu-
died. All animals were conditioned and manipulated
according to Canadian Council on Animal Care guidelines.
They were housed in pairs, in standard laboratory cages,
and kept in an air-conditioned animal room at a tempera-
ture of 22°C ± 2°C and relative humidity of 57 ± 2% under
a 12-h light/12-h dark cycle with ad libitum access to food
and water. The experimental protocol was approved by
the Research Ethics Board of Hôpital du Sacré-Cœur de
Montréal. AIA was produced with complete Freund’s
adjuvant (CFA) containing heat-killed Mycobacterium
butyricum (Difco, Detroit, MI, USA) in mineral oil at
10 mg/ml, as described previously [24]. The rats were
injected intradermally with 100 μl of adjuvant at the base
of the tail. Arthritis developed 10 days later. The rats were
allocated to five groups, each consisting of six animals.
Group 1, serving as control, received a 100 μl injection of
mineral oil. Group 2 was given 10 mg/kg/day of ramipril
alone by oral gavage. Group 3 was injected with 100 μl of
CFA and represented the AIA model. Group 4 was given a
100 μl injection of CFA with 10 mg/kg/day of ramipril by
oral gavage. Group 5 received a 100 μl injection of CFA
with 10 mg/kg/day of 0.01% dimethyl sulfoxide (DMSO)
as vehicle by oral gavage. Treatment was initiated on day 1
of the study and continued through day 28. All groups
were sacrificed on day 28, when maximum inflammation
occurred.
Specimen selection
At the end of the study, the animals were anesthetized
with xylazine/ketamine (10/50 mg/kg, intraperitoneally),
and blood was collected in tubes by cardiac puncture
before sacrifice. Blood samples were immediately centri-
fuged at 3,000 rpm for 10 min, and serum samples were
stored at -80°C before they were used. LV tissues were iso-
lated, freeze-clamped, and stored in liquid nitrogen until
further analyses.
Arthritis scoring
Arthritis severity was evaluated, as described previously
[25], by monitoring the forepaws and hind paws twice a
week for visual signs of inflammation, such as erythema
and swelling, according to the following macroscopic
scoring system. 0: no signs of arthritis, 1: swelling and/
or redness in one paw, 2: two joints affected, 3: more
than two joints affected, and 4: severe arthritis in all
paws. Paw diameters were measured twice a week.
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Tissue levels of HNE-protein adducts
Total tissue levels of HNE-protein adducts were assessed
in serum from animal groups by in-house enzyme-linked
immunosorbent assay (ELISA), as described previously
[26]. HNE-modified bovine serum albumin (BSA, Sigma-
Aldrich, Oakville, ON, Canada) served as standard.
Enzyme activity
Total mNADP-ICDH activity was quantified in 100 mg of
powdered LV tissues that were homogenized on ice in
1 ml of lysis buffer composed of 25 mM Tris-HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol
supplemented with protease inhibitor cocktail. The homo-
genate was then centrifuged for 10 min at 800 × g at 4°C.
The supernatants were used for enzyme assay after
10-min centrifugation at 6,000 × g at 4°C. Protein levels
were determined using bicinchoninic acid (BCA) protein
assay reagent (Thermo Fisher Scientific, Rockford, IL,
USA) with BSA (Sigma-Aldrich) as standard. The activity
of mNADP-ICDH was assayed as the rate of NADP reduc-
tion (340 nm, ε = 6200 M -1·cm-1) upon addition of
10 mM isocitrate, 1 mM NADP and 0.1 mM MgCl2 to
50 μg/ml of total proteins, as described previously [27].
Activities are expressed in units/mg of proteins, where 1
unit is defined as the amount of enzyme catalyzing the
conversion of 1 μmol substrate/min at 37°C.
Protein detection by Western blotting
Proteins from roughly 50 mg of powdered LV tissues were
extracted, as described above. After protein determination,
20 μg of total proteins from heart tissues were subjected
to discontinuous 4-12% sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE). Protein transfer
and immunodetection as well as semi-quantitative mea-
surements were taken, as outlined previously [27]. The pri-
mary antibodies were rabbit anti-mNADP-ICDH (Abcam,
Cambridge, MA, USA), rabbit anti-angiotensin II receptor
type 1 (AT1R) (Pierce Biotechnology, Inc., Rockford, IL,
USA), anti-b-actin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-HNE (Cayman Chemical Company, Ann
Arbor, MI, USA), and anti-type I collagen (Col I) and anti-
connective tissue growth factor (CTGF) (Millipore, Etobi-
coke, ON, Canada). After serial washes with Tris-buffered
saline + Tween, primary antibodies were detected by goat
anti-rabbit IgG conjugated with horseradish peroxidase
(Cell Signaling Technology, Danvers, MA, USA). Immu-
noreactive proteins were quantified with SuperSignal blot-
ting substrate (Thermo Fisher Scientific) and exposed to
clear-blue X-ray film (Thermo Fisher Scientific).
Immunoprecipitation
For the in vivo detection of HNE/mNADP-ICDH
adducts, 100 μg of total protein, prepared as indicated
above, were subjected to overnight immunoprecipitation
with 1 μg of rabbit anti-mNADP-ICDH (Abcam) in lysis
buffer at 4°C with constant, gentle shaking and then for
2 more hours with protein A (Santa Cruz Biotechnol-
ogy), as described previously [27]. The resin was washed
with lysis buffer, and proteins were removed from the
resin by the addition of 100 μl undiluted SDS-loading
buffer. A 20-μl aliquot of immunoprecipitated proteins
was heated at 95°C for 3 min prior to Western blot ana-
lysis, with rabbit anti-HNE as primary antibody (1:1,000
dilution; Cayman Chemical Company).
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA was isolated with TRIzol reagent according to
the manufacturer’s instructions (Invitrogen, Burlington,
ON, Canada). RNA was measured with RiboGreen RNA
quantitation kits (Molecular Probes, Eugene, OR, USA),
dissolved in diethylpyrocarbonate-treated H2O, and
stored at -80°C until used. One μg of total RNA was
reverse-transcribed with Moloney murine leukemia virus
reverse transcriptase (Fermentas, Burlington, ON,
Canada), as detailed in the manufacturer’s guidelines.
One-fiftieth of the reverse transcriptase reaction product
was analyzed by traditional PCR or real-time quantitative
(q) PCR [28]. The following sense and anti-sense specific
primers (Bio-Corp, Inc., Montreal, QC, Canada), were
tested: rat mNADP-ICDH (forward) 5’-ATG TGG AAG
AGC CCT AAC GGA ACT-3’, (reverse) 5’-ACA TGC
CAG CTC GAT CTA CCA CAA-3’; rat AT1R (forward)
5’-CGG CCT TCG GAT AAC ATG AG-3’, (reverse) 5’-
CCT GTC ACT CCA CCT CAA AAC A-3’; rat GAPDH
(forward) 5’-GCA TTG ATG GTG AGG TGA GCA AA-
3’, (reverse) 5’-TCG CTC CTG GAA GAT GGT GA-3’.
qPCR analysis was performed in a total volume of 50 μl
containing template DNA, 200 nM sense and anti-sense
primers, 25 μl of SYBR Green Master Mix (Qiagen,
Mississauga, ON, Canada), and 0.5 units of uracil-N-
glycosylase (UNG; Epicentre Technologies, Madison, WI,
USA). After incubation at 50°C for 2 min (UNG reaction)
and at 95°C for 10 min (UNG inactivation and activation
of AmpliTaq Gold enzyme), the mixtures were subjected
to 40 amplification cycles (15 s at 95°C for denaturation
and 1 min for annealing and extension at 60°C). SYBR
Green dye incorporation into the PCR products was
monitored in real time with a Mx3000 real-time PCR sys-
tem (Stratagene, La Jolla, CA, USA), to determine the
threshold cycle (Ct) at which exponential amplification of
PCR products begins. After PCR, dissociation curves
were generated with 1 peak indicating amplification spe-
cificity. A Ct value was obtained from each amplification
curve with software provided by the manufacturer
(Stratagene).
Relative mRNA expression in chondrocytes was quanti-
fied according to the ΔΔCt method, as detailed in the
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manufacturer’s guidelines (Stratagene). A ΔCt value was
first calculated by subtracting the Ct value for the house-
keeping gene GAPDH from the Ct value for each sample.
A ΔΔCt value was then calculated by subtracting the ΔCt
value for the controls (unstimulated cells) from the ΔCt
value for each treatment. Fold changes compared to the
controls were then quantified by 2-ΔΔCt. Each PCR gener-
ated only the expected specific amplicon, as shown by
melting temperature profiles of the final product and gel
electrophoresis of the test PCRs. Each PCR was per-
formed in triplicate on two separate occasions for each
independent experiment.
Prostaglandin E2 (PGE2) and tumour necrosis factor-alpha
(TNFa immunoassay
PGE2 and TNFa levels were measured in serum by
enzyme immunoassay or ELISA, with kits from the Cay-
man Chemical Company and R&D Systems (Minneapolis,
MN, USA), respectively. Detection sensitivity was 9 pg/ml
for PGE2 and 4.4 pg/ml for TNFa. Each assay was run
according to the manufacturer’s specifications.
Evaluation of tissue fibrosis by picrosirius red staining
Tissue samples embedded in Tissue Fix were transferred
after 24 h in a formalin-ethanol solution (50/50%) until
they were sliced longitudinally. They were then stained
with picrosirius red (Sigma-Aldrich) and examined under
circularly polarized light to visualize interstitial collagen
from its red coloration [29]. Photographs were taken, and
the surface staining for collagen was calculated as a per-
centage of the total surface with the use of the National
Institutes of Health program ImageJ.
Cardiomyocytes isolation
Adult cardiomyocytes were isolated from female Lewis
rats, as we described previously [30]. The resulting hydro-
lysate was filtered to remove cell clumps and depleted of
fibroblasts by two 35-min preplatings at 37°C, in Dulbec-
co’s modified Eagle’s minimal essential medium (DMEM,
Invitrogen) containing 10% fetal bovine serum (FBS, Invi-
trogen). The non-adhered cardiomyocyte suspension was
centrifuged, resuspended in DMEM + 10% FBS, seeded in
12-well plates at an approximate density of 2 × 105 cells/
cm2, and incubated for 24 h at 37°C in an atmosphere of
5% CO2. The spent medium was replaced by serum-free
DMEM medium supplemented with the following pro-
ducts supplied by Sigma-Aldrich: 1% BSA, 1× vitamins, 1×
nonessential amino acids, 0.5× essential amino acids,
6.25 μg/ml insulin, 6.25 μg/ml transferrin, 6.25 ng/ml
sodium selenite, 80 μg/ml CaCl2, 50 U/ml penicillin,
50 μg/ml streptomycin, and 20 μM cytosine-b-D-arabino-
furanoside. The culture was maintained at 37°C for 48 h in
a humidified atmosphere containing 5% CO2/95% air in
the presence or absence of 10 μM HNE and/or 10 μM
ramipril.
Quantification of reduced glutathione (GSH), oxidized
glutathione (GSSG) and NADPH levels
Powdered LV tissues (50 mg) were homogenized on ice
in 1 ml of lysis buffer containing 0.2 M 2-(N-morpho-
lino)ethanesulfonic acid, 0.05 M potassium phosphate,
and 1 mM EDTA, pH 6.0. The homogenates were then
centrifuged for 10 min at 800 × g at 4°C followed by
another centrifugation for 10 min at 10,000 × g at 4°C.
The protein content of tissue extracts was determined
using BCA protein assay reagent (Pierce), with BSA
(Sigma-Aldrich) as standard. GSH and NADPH levels
were quantified with a GSH Assay Kit (Cayman Chemi-
cal Company) and NADP/NADPH Assay Kit (Abcam)
according to the manufacturers’ directions. The quantifi-
cation of GSSG was accomplished by derivatizing GSH
by adding vinylpyridine to total proteins. Values were
expressed as GSSG/(GSSG+GSH) and NADP/(NADP
+NADPH) ratios.
Statistical analysis
The data are expressed as means ± SEM of six rats. All
statistics were generated by Prism software (GraphPad
Software, San Diego, CA, USA). Statistical significance
was assessed by one-way ANOVA, followed by the Bon-
ferroni multiple-comparison post test, and P < 0.05 was
considered significant.
Results
Serum TNFa and PGE2 levels and clinical evaluation
First, we tested ramipril ability to reduce inflammation
and arthritis markers in our experimental RA model.
Serum TNFa and PGE2 levels were measured to evaluate
the extent of inflammation process. Hind paw swelling
and arthritis scores were recorded. These markers reflect
both inflammatory and arthritic changes occurring in
rats with AIA. As shown in Figure 1, TNFa (Figure 1A)
and PGE2 (Figure 1B) levels were significantly higher in
rats with AIA (approximately 8-fold increase, P < 0.01)
than in the controls. In comparison to arthritic animals,
however, ramipril-treated rats displayed a significant
decrease in serum TNFa and PGE2 levels (approximately
2.6-fold diminution, P < 0.05). Furthermore, our data
revealed that oral ramipril administration to adjuvant-
immunized rats reduced the progression of arthritis
by inhibiting the increase in paw swelling (Figures 1C
and 1D) and arthritis score (Figures 1C and 1E) com-
pared to arthritic rats. None of the indicated parameters
including TNFa, PGE2 and arthritis scoring was changed
in control AIA rats receiving DMSO (data not shown) or
control animals receiving ramipril alone.
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Figure 1 Pro-inflammatory cytokines determination and clinical evaluation of adjuvant-induced arthritis (AIA). (A) Tumor necrosis factor-
alpha (TNFa) and (B) prostaglandin E2 (PGE2) were assessed in serum from control and AIA rats with ELISA. (C-E) Clinical evaluation was
performed by measuring paw swelling (C, D) and arthritis score (C, E). Data are mean ± SEM of three experiments. Statistics: one-way ANOVA,
*P < 0.05, **P < 0.01, ***P < 0.001 (CTL versus AIA), #P < 0.05 (AIA versus AIA+Ram). CTL, control; Ram, ramipril.
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The LPO end-product HNE is increased in serum and LV
tissues of AIA rats
Here, we looked for evidence of increased oxidative stress
in LV tissues from AIA rats, by quantification of HNE, a
very reactive product of LPO, in both serum and LV tis-
sues. As illustrated in Figure 2A, HNE levels rose in the
serum and LV tissues of AIA rats by 3.3- (P < 0.01) and
2-fold (P < 0.05) respectively compared to control rats.
The corresponding profile of HNE/protein adducts gen-
erated in LV tissues is charted in Figure 2B. As can be
seen, the intensity of immunoreactive bands increased in
LV tissues from AIA rats in comparison to controls, and
most had a molecular weight ≥40 kDa. Interestingly, the
accumulation of cardiac HNE/protein adducts was signif-
icantly abolished by ramipril administration in both
serum and LV tissues (P < 0.05). No significant changes
in HNE production was noted in control AIA rats receiv-
ing DMSO (data not shown) or control animals receiving
ramipril alone (Figure 2).
Cardiac mNADP-ICDH is impaired in AIA rats
To establish whether mitochondrial bioenergetics/redox
status were impaired in the heart of AIA rats, we
assessed the activity and the expression of mNADP-
ICDH, an enzyme whose activity is a determinant of
mitochondrial energy and oxidative stress status. We
observed that mNADP-ICDH activity decreased by 25%
(P < 0.01, Figure 3A) in LV tissues. In contrast, its pro-
tein (Figure 3B) and mRNA (Figure 3C) expression
levels remained unchanged.
We then tested the hypothesis of potential mNADP-
ICDH modification by HNE. Our choice of HNE is based
on previous reports indicating that mNADP-ICDH is tar-
geted for HNE binding in heart hypertrophy in sponta-
neously hypertensive rats (SHR) [27]. Data derived by the
immunoprecipitation approach, using rabbit anti-
mNADP+-ICDH antibody followed by Western blotting
with rabbit anti-HNE antibody, showed a 2.5-fold (P <
0.01) increase in relative HNE/mNADP-ICDH adduct
levels in heart tissues from AIA rats compared to con-
trols (Figure 3D). Interestingly, all changes in this enzyme
were prevented by oral treatment with ramipril. However,
the administration of DMSO (data not shown) or rami-
pril had no effect on mNADP-ICDH activity/expression
in AIA and control rats, respectively. Taken together, our
results indicate the existence of a post-translational
mechanism decreasing cardiac mNADP-ICDH activity
during the RA process.
Alteration of cardiac redox status in AIA rats
Because impairments of mNADP-ICDH activity/expres-
sion were demonstrated to be associated with alterations
in oxidative stress status [31], we evaluated whether
changes in this enzyme were paralleled by similar
modifications of NADPH, a co-factor involved in GSH
generation. Figure 4 depicts a significant 30% decrease
(P < 0.05) of NADPH and GSH pools in LV tissues of AIA
rats compared to controls. The impairment of cardiac
redox status was restored by ramipril. No significant
changes in redox status were apparent in AIA rats receiv-
ing DMSO (data not shown) or control animals receiving
ramipril alone. Collectively, these findings suggest that
alteration of myocardial redox status could be due to
mNADP-ICDH inactivation.
Cardiac fibrosis was increased in AIA rats
First, a pair of experiments was designed to verify the
expression of heart fibrosis markers in AIA rats. Our
findings illustrated in Figure 5 showed that AT1R pro-
tein (Figure 5A) and mRNA (Figure 5B) levels were
respectively 4.5- (P < 0.001) and 2.1-fold (P < 0.01)
higher in LV tissues from AIA rats as compared to con-
trols. Ramipril attenuated the elevation of AT1R protein
and mRNA expression in agreement with the drug’s
capacity to prevent cardiac hypertrophy [32]. Altogether,
our data suggested that increased tissue AT1R expres-
sion could potentiate heart hypertrophy and hyperplasia
in AIA rats.
Second, another set of experiments were performed to
document cardiac fibrosis in each animal group. As illu-
strated in Figure 5C, when microscopic images prepared
from each groups were compared, a significant increase
of collagen content (calculated as a percent of total sur-
face) was observed in LV tissues from AIA rats as com-
pared to controls (CTL: 1.5 ± 0.12, RA: 2.9 ± 0.35, **P <
0.01). However, the oral administration of ramipril sig-
nificantly reduced the collagen deposition in the tissue
(1.9 ± 0.14, #P < 0.05). No significant changes in cardiac
fibrosis were noted in AIA rats receiving DMSO (data
not shown) or control animals receiving ramipril alone.
HNE induced mNADP-ICDH inactivation as well as Col I
and CTGF expression in vitro
To confirm the in vivo observation, we conducted a series
of in vitro experiments that mimicked the in vivo situa-
tion during RA development. First, we investigated the
effect of HNE on mNADP-ICDH in isolated rat cardio-
myocytes. As illustrated in Figure 6, treatment of cells
with 10 μM HNE for 48 h reduced mNADP-ICDH activ-
ity by approximately 30% (P < 0.05, Figure 6A) and
increased HNE/mNADP-ICDH adducts by 3.1-fold (P <
0.001, Figure 6B). To evaluate the ability of HNE to
induce markers of fibrosis, cells were treated in the indi-
cated conditions. Figure 6C showed that HNE induced
Col I and CTGF by 4- (P < 0.001) and 2.8-fold (P <
0.001), respectively. Nevertheless, all HNE effects were
abolished by 10 μM ramipril. Collectively, these findings
are in agreement with the in vivo results and confirm the
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potential role of HNE in mNADP-ICDH inactivation and
fibrosis induction in the heart.
Discussion
The present study provides clear evidence of increased car-
diac fibrosis and oxidative stress status in an experimental
rat model of RA. This model is robust, the incidence rate
of the disease is 100%, and AIA in rats shares many fea-
tures with RA in humans, such as inflammation, marked
bone resorption and periosteal bone proliferation [33]. AIA
in rats has been widely adopted as an experimental para-







































































Figure 2 Quantification and characterization of 4-hydroxynonenal (HNE)/protein adducts by enzyme-linked immunosorbent assay
(ELISA) and Western blotting. (A) HNE/protein adducts were measured by ELISA in serum and left ventricular (LV) tissues from control and
adjuvant-induced arthritis (AIA) rats (n = 6). (B) HNE/protein adducts were characterized by Western blotting in total proteins of LV tissues from
control and AIA rats. Values are the mean ± SEM of three experiments. *P < 0.05; **P < 0.01 (CTL versus AIA), #P < 0.05 (AIA versus AIA+Ram) by
one-way ANOVA. CTL, control; Ram, ramipril.
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In this model, we measured markers of RA. Our data
showed an increase of paw diameter, arthritis scores and
inflammatory mediator levels in serum known to be
involved in the RA process, such as TNFa and PGE2, in
AIA rats. These findings are in agreement with our pre-
vious study indicating an elevation of these pro-inflamma-
tory mediators in serum from AIA rats [24]. In RA,
fibroblast-like synoviocytes and inflammatory cells produce
a panoply of pro-inflammatory mediators, such as IL-1b,
TNFa, and PGE2, which play key roles in the pathogenesis
of RA. They promote inflammation, hyperplasia, and bone
and cartilage destruction [34].
In view of its potential pathophysiological significance,
we first investigated oxidative stress status in heart tis-
sues. Reactive oxygen species (ROS), which likely contri-
bute to the pathophysiology of endothelial dysfunction,
were shown to be overproduced in the aorta of rats with
AIA [35]. ROS can damage cellular components by
direct oxidation; however, given the susceptibility of
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Figure 3 Cardiac mitochondrial NADP+-dependent isocitrate dehydrogenase (mNADP-ICDH) activity (A), protein (B), and mRNA (C).
Total proteins and RNA were extracted from left ventricular (LV) tissues of control and adjuvant-induced arthritis (AIA) rats and processed to
enzymatic assay (A), Western blotting (B) or real-time PCR (C), as described under Materials and Methods. (D) Cardiac 4-hydroxynonenal (HNE)/
NADP-ICDH adducts were identified in total proteins by immunoprecipitation as described in Material and Methods. Values are the mean ± SEM



































Figure 4 Determination of cardiac redox status. Glutathione
(GSH) and nicotinamide adenine dinucleotide phosphate (reduced)
(NADPH) were determined in total proteins extracted in left
ventricular (LV) tissues from control and adjuvant-induced arthritis
(AIA) rats. Data are mean ± SEM of three experiments and
expressed as GSSG/(GSSG+GSH) and NADP/(NADP+NADPH) ratio.
Statistics: one-way ANOVA; *P < 0.05 (CTL versus AIA), #P < 0.05 (AIA
versus AIA+Ram). CTL, control; Ram, ramipril.
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Figure 5 Measurement of cardiac remodeling in left ventricular (LV) tissues from control and adjuvant-induced arthritis (AIA) rats. (A, B)
Expression of angiotensin II type I receptor (AT1R) LV from AIA rats. Total proteins and RNA were extracted in LV tissues of control and AIA rats and
processed to AT1R protein (A) and mRNA (B) determination by Western blotting and real-time PCR, respectively. (C) Cardiac collagen content in LV
tissues was detected by the picosirius red polarization method. Histological sections obtained from control and AIA rats were stained with
picosirius red solution and examined under circularly polarized light to visualize interstitial collagen by its red coloration. Surface staining for
collagen was calculated as a percentage of the total surface. Values are the mean ± SEM of three experiments. **P < 0.01, ***P < 0.001 (CTL versus
AIA), #P < 0.05, &P < 0.01 (AIA versus AIA+Ram) by one-way ANOVA. CTL, control; Ram, ramipril.
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Figure 6 Modulation of mitochondrial NADP+-dependent isocitrate dehydrogenase (mNADP-ICDH), type I collagen (Col I) and
connective tissue growth factor (CTGF) in isolated adult rat cardiomyocytes. Cells were treated with 10 μM 4-hydroxynonenal (HNE) for 48
hours in the presence or absence of 10 μM ramipril and then total proteins were preceded to the determination of (A) NADP-ICDH activity, (B)
HNE/NADP-ICDH adducts, and (C) Col I and CTGF protein as described in Materials and Methods. Values are the mean ± SEM of three
experiments. *P < 0.05, ***P < 0.001 (CTL versus HNE), #P < 0.05, &P < 0.01 (HNE versus HNE+Ram) by one-way ANOVA. CTL, control; Ram,
ramipril.
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polyunsaturated fatty acids to oxidative attacks, there is
a strong rationale for invoking the involvement of sec-
ondary products of LPO, such as HNE and acrolein, in
ROS-related injury. Our data disclosed an increase of
HNE levels in both serum and heart tissues from AIA
rats. These observations are in agreement with previous
data reported by Choi [2], showing an increase of mal-
ondialdehyde, protein carbonyl and advanced glycation
end-products in the heart of AIA rats. The fact that
activation of HNE-detoxifying enzymes protects the
heart from ischemic injury suggests that HNE is a sig-
nificant contributor to myocardial damage [36]. Many
studies have shown that HNE damages electron trans-
port chain complexes [37-39], affecting both cell respira-
tion and critical events, such as calcium-induced
permeability transition [40]. Considering these results,
it is likely that extensive formation of HNE/protein
adducts causes damage to mitochondrial energy metabo-
lism that culminates in altered heart function. Increased
oxidative stress and/or changes of fuel metabolism are
among factors that contribute to the development of
cardiac hypertrophy and its progression to HF, regard-
less of disease etiology [41].
Second, our findings revealed that mNADP-ICDH
activity was decreased in heart tissues from AIA rats
without changes in its expression at protein and mRNA
levels. Inactivation of this enzyme was associated with
the formation of HNE/mNADP-ICDH adducts. In our
previous study, we reported elevated HNE/protein
adducts levels in SHR compared to Wistar-Kyoto rat
hearts [27]. Specifically, the post-translational modifica-
tion of mNADP-ICDH by HNE precedes cardiac hyper-
trophy development. In addition to its critical role in the
regulation of mitochondrial energy, mNADP-ICDH has
received considerable attention as a principal source of
NADPH, a co-factor involved in GSH regeneration [31].
The generation of GSH by GSH reductase increases the
mitochondrial capacity for HNE detoxification through
GSH conjugation and export [42]. In the present study,
we found a decrease in NADPH and GSH pools, probably
attributed to mNADP-ICDH inactivation. We speculate
that in the heart, where mNADP-ICDH favors the gen-
eration of a-ketoglutarate and NADPH, mNADP-ICDH
inactivation by HNE could compromise mitochondrial
energy metabolism and redox status.
To confirm the in vivo data, we conducted additional
experiments on isolated adult rat cardiomyocytes treated
with HNE, an in vitro approach designed to mimic the
in vivo situation during RA process. Interestingly, results
revealed that HNE inhibits mNADP-ICDH activity and
augments HNE/mNADP-ICDH adduct levels, indicating
an impairment of mitochondrial function. The mechan-
ism causing this inactivation could reside in HNE ability
to bind to a cysteine residue near the substrate’s binding
site [27]. In another study, it has been reported that nitric
oxide (NO) inhibits the activity of mNADP-ICDH [43],
through S-nitrosylation of cysteine residues on this
enzyme. The NO-mediated damage to mNADP-ICDH
results in the perturbation of the cellular antioxidant
defense mechanisms and subsequently leads to a pro-oxi-
dant condition. Taken together, our data provide direct
in vivo and in vitro evidence that oxidative stress contri-
butes to mNADP-ICDH inactivation in conjunction with
the formation of HNE/mNADP-ICDH adducts. Addi-
tional work is needed, however, to evaluate the specific
significance of mNADP-ICDH inactivation (via HNE
binding) in cardiac dysfunction in RA.
Third, our data showed that cardiac fibrosis is higher
in AIA rats. On one hand, we demonstrated an increase
of tissue fibrosis in LV tissues of AIA rats. Fibrosis is a
hallmark of CV diseases and is often associated with
inflammation. It has been proposed that mediators of
inflammation, including cytokines such as TNFa, IL1b,
and IL-6, leads to microvascular dysfunction and ulti-
mately to myocardial remodeling and fibrosis [44,45].
Augmented fibrosis in the heart is linked with ventricu-
lar remodeling and subsequent cardiac dysfunction and is
therefore a common pathological feature of many types
of HF [46]. Traditionally, cardiac fibroblasts were thought
to be activated by pro-inflammatory processes to prolifer-
ate and synthesize collagen that is secreted and deposited
in the interstitial space [47]. Transgenic mice with
targeted overexpression of TNFa develop progressive
myocardial fibrosis, diastolic dysfunction, and adverse
cardiac remodeling [48]. Furthermore, it has been
reported that cardiac remodeling was markedly exacer-
bated in mice that express high level of human C-reactive
protein (CRP), resulting in a significant reduction in the
LV ejection fraction and fractional shortening and an
increase in cardiac fibrosis (Col I and III) and inflamma-
tion (IL-1b and TNFa). The enhancement in cardiac
remodeling in mice that express human CRP was asso-
ciated with further upregulation of the AT1R [49].
Furthermore, the greater increase of HNE levels in the
heart of AIA rats would play a key role in the pathogen-
esis of fibrosis. In isolated cardiomyocytes, we revealed
the capacity of HNE to induce Col I and CTGF. These in
vitro data suggest that HNE may act as a potent pro-
fibrogenic stimulus in the heart. In fact, many studies
have shown that LPO products play a key role in the
initiation and progression of fibrosis in different organs
[50]. During liver injury, Zamara et al. [51] have indi-
cated that HNE favor extracellular matrix deposition by
its ability to upregulate Col I and tissue inhibitors of
metalloproteinase-1 (TIMP-1) expression. On the other
hand, we noted a significant increase of AT1R in heart
tissues from AIA rats. These findings are consistent with
those reported by Sakuta et al. [52], who demonstrated
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that AT1R and ACE expression was heightened in the
aortas of rats with AIA, suggesting the involvement of
renin-angiotensin system (RAS) in vascular damage in an
animal model of autoimmune/inflammatory disease. The
mechanism underlying the upregulation of AT1R in RA
remains unclear. It has been shown that circulating pro-
inflammatory cytokines influence the vascular expression
of AT1R. IL-6 is of particular interest, since it has been
demonstrated to induce the upregulation of AT1R gene
and protein expression in rat cultured vascular smooth
muscle cells and in mouse vascular tissue [53].
Finally, our findings of enhanced markers of cardiac
oxidative stress and fibrosis as well as arthritis scoring
were prevented by ramipril administration in AIA rats. It
is well established that RAS activation by an agonist of
AT1R results in cardiac fibrosis, inflammation, oxidative
stress and congestive heart failure via AT1 receptor acti-
vation [54]. The latter mediates effects such as vasocon-
striction, cellular proliferation, and matrix deposition
[55,56], most likely via a mechanism that involves
enhanced free radical production due to stimulated
NADPH oxidase activity [57,58]. Angiotensin II (Ang II)
stimulates the expression of NF-B, a transcription factor
that regulates gene expression of inflammatory cytokines
and surface adhesion molecules, leading to inflammation
[59]. NF-B activation may result from increased oxida-
tive stress, which may be induced by Ang II [60]. Inter-
estingly, it has been reported that Ang II-induced
myocardial molecular/cellular events and their relation to
oxidative stress, inflammation and fibrosis are attributed,
in part, to the production of mineralocorticoids such as
aldosterone [61]. It also produces a variety of other
actions that lead to progressive damage in the heart, vas-
culature, and kidneys [62,63]. Although Ang II is consid-
ered to be the major mediator of cardiovascular damage,
it was suggested that aldosterone may mediate and
exacerbate the effects of Ang II [58,61]. Blocking of the
mineralocorticoid receptor and inhibition of ACE and/or
the AT1R reduced aldosterone release and markers of
fibrosis and oxidative stress.
The use of ACE inhibitors in patients with RA has
attracted much interest in recent years. Flammer et al. [8]
reported that ramipril markedly improved endothelial
function in RA patients, by reducing the levels of pro-
inflammatory cytokines. However, arthritis activity score
remained unaltered after treatment with ramipril. These
data contrast with those reported by Tikiz et al. [64]
which showed no significant changes in vasodilatation,
CRP and TNFa in RA patients treated with quinapril. The
authors attributed the lack of quinapril efficacy to impro-
per dosage or length of treatment. In an experimental
model of RA, Dalbeth and colleagues [65] observed that
the ACE inhibitor quinapril and the AT1R inhibitor cande-
sartan suppressed the severity of collagen-induced
arthritis. Interestingly, they noted that paw TNFa concen-
tration was reduced in mice receiving quinapril compared
to those administered water and that decreased TNFa
levels were not a consequence of suppressed disease activ-
ity. More recently, Sakuta et al. [52] noted an increase in
AT1R and ACE expression in the aortas of rats with AIA.
In addition to ACE inhibitors, the administration of AT1R
blockers decreased the oxidative stress as measured by
superoxide generation and NADPH oxidase expression in
the aortas of rats with AIA [52].
Conclusions
Our findings showed for the first time that myocardial
abnormalities are observed in AIA rats. These include
increase in oxidative stress and tissue fibrosis and altera-
tion in cell metabolism. The findings also inform new
hypothesis for the role of HNE in myocardial abnormal-
ities through its ability to inhibit mNADP-ICDH activity
and to induce CTGF and Col I expression in isolated
cardiomyocytes. Potentially, it could contribute to the
etiology of cardiomyopathy. Furthermore, our data sug-
gest that ACE inhibition may provide a novel strategy to
prevent CV events in RA.
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